U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Cefotaxime – Injection products
  1. Development Resources

Cefotaxime – Injection products

 

Minimum Inhibitory
Concentrations

(mcg/mL)

Disk Diffusion
(zone diameter in mm)

Pathogen

S

I

R

S

I

R

Enterobacteralesa

M100 standard is recognized

Acinetobacter spp.

≤1

2

≥4

-

-

-

Other non-Enterobacterales

≤1

2

≥4

-

-

-

Haemophilus influenzae and parainfluenzae

≤1

-

-

-

-

-

Neisseria gonorrhoeae

M100 standard is recognized

Streptococcus pneumoniae
(meningitis)

M100 standard is recognized

-

-

-

Streptococcus pneumoniae
(non-meningitis)

M100 standard is recognized

-

-

-

Streptococcus spp β- Hemolytic Group

M100 standard is recognized

Streptococcus spp Viridans Group

M100 standard is recognized

Neisseria meningitidis

M100 standard is recognized

Anaerobes

≤1

2

≥4

-

-

-

aIncluding Salmonella spp. and Shigella spp.

S = Susceptible; I = Intermediate; R = Resistant

Back to Top